|
Oct 3
|
Is Verve Therapeutics, Inc. (VERV) the Best NASDAQ Stock Under $5?
|
|
Jun 21
|
One Verve Therapeutics Insider Raised Stake By 29% In Previous Year
|
|
May 11
|
Verve Therapeutics, Inc. (NASDAQ:VERV) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
|
|
May 10
|
Analysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This Week
|
|
May 9
|
Verve Therapeutics First Quarter 2024 Earnings: Beats Expectations
|
|
May 8
|
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 8
|
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
|
|
May 7
|
Verve moves forward with backup base editing therapy
|
|
May 7
|
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
|
|
Apr 25
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
|
Apr 6
|
After a Serious Setback, Is Verve Therapeutics a Buy?
|
|
Apr 4
|
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
|
|
Apr 3
|
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
|
|
Apr 2
|
Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects
|
|
Apr 2
|
Verve Falls as Gene-Editing Trial Paused on Safety Issues
|
|
Apr 2
|
UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
|
|
Apr 2
|
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
|
|
Apr 2
|
Verve Therapeutics Announces Updates on its PCSK9 Program
|
|
Apr 2
|
Verve pauses base editing trial, shifts strategy after treatment side effect
|
|
Mar 28
|
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|